Why Older Adults Get Less Protection From Flu and Shingles Vaccines
A completed Phase 2 trial investigates the immune mechanisms behind age-related vaccine failure in older adults.
Summary
Vaccines often work less well in older people, but the biological reasons remain poorly understood. This completed Phase 2 trial from Radboud University Medical Center compared immune responses in young versus older adults following vaccination with a quadrivalent influenza vaccine and the adjuvanted Shingrix herpes zoster vaccine. By examining the underlying immunological differences between age groups — including both antibody production and cellular immune responses — researchers aimed to identify mechanisms driving this reduced vaccine effectiveness. The findings could inform the development of next-generation vaccines better tailored to aging immune systems. Understanding immune senescence in the context of real-world vaccines is a critical step toward improving protection for the population most vulnerable to influenza and shingles complications.
Detailed Summary
As global populations age, one of the most pressing challenges in preventive medicine is the declining effectiveness of vaccines in older adults. The immune system undergoes profound changes with age — a process known as immunosenescence — that blunts both antibody and cellular responses to vaccination. Yet the precise mechanisms behind this blunting remain incompletely understood, limiting our ability to engineer better solutions.
This single-centre, open-label, partially randomised, partially placebo-controlled Phase 2 trial enrolled both young and older adult participants at Radboud University Medical Center in the Netherlands. Participants received a quadrivalent inactivated influenza vaccine (Fluarix Tetra, GSK) and an adjuvanted recombinant herpes zoster vaccine (Shingrix, GSK), with placebo controls incorporated into the design. The dual-vaccine approach allowed researchers to compare age-related immune differences across two distinct vaccine platforms simultaneously.
The trial has been completed, but detailed results are not yet publicly available in this abstract. The primary goal was to characterize immunological differences — including humoral and cellular immune responses — between younger and older participants, shedding light on why protection wanes with age.
The clinical implications are significant. Influenza and herpes zoster both carry disproportionate morbidity and mortality burdens in older adults. If researchers can pinpoint the immune checkpoints that fail with aging, vaccine developers could design adjuvants, delivery systems, or dosing regimens specifically optimized for older immune systems.
Caveats apply: the trial is single-centre and of modest Phase 2 scale, limiting generalizability. Full results including quantitative immunogenicity data, adverse event profiles, and mechanistic findings have not yet been published. This summary is based on the abstract only, and conclusions about efficacy or specific immune findings cannot be drawn until peer-reviewed data are available.
Key Findings
- Trial directly compares vaccine immune responses between young and older adults using two distinct GSK vaccines.
- Shingrix (adjuvanted herpes zoster vaccine) included to probe whether adjuvants can overcome age-related immune decline.
- Mechanistic focus: identifying biological pathways behind reduced vaccine immunogenicity in older adults.
- Findings could guide development of age-optimized vaccines for the populations most vulnerable to flu and shingles.
- Trial completed at Radboud University Medical Center; full immunogenicity results pending publication.
Methodology
Single-centre, open-label, partially randomised, partially placebo-controlled Phase 2 trial enrolling young and older adult cohorts. Participants received quadrivalent inactivated influenza vaccine and adjuvanted herpes zoster vaccine (Shingrix), with placebo controls. The design enables head-to-head comparison of immunological responses across age groups using two mechanistically distinct vaccine platforms.
Study Limitations
This summary is based on the abstract only; full immunogenicity results, mechanistic data, and adverse event profiles have not been published and cannot be evaluated. The single-centre design limits generalizability across diverse populations. Phase 2 scale means the trial is powered for immunogenicity signals, not definitive efficacy conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.